Introduction The coronavirus disease-2019 (COVID-19) has emerged as a novel infection which has spread rapidly across the globe and currently presents a grave threat to the health of the cancer patient. Objective The aim of this meta-analysis was to evaluate the proportion of hematological cancer patients with the SARS-CoV-2 infection during the COVID-19 pandemic. Method A comprehensive literature review was performed on PubMed, Web of Science, Scopus, EKB SciELO, SID, CNKI and Wanfang databases to retrieve all relevant publications up to January 31, 2021. Observational studies, consecutive case-series and case-control studies were included. The proportion for hematological cancer patients with COVID-19 was estimated using the odds ratios (ORs) and 95% confidence interval (95% CIs). Results Fourteen studies with a total of 3,770 infected cancer patients and 685 hematological cancer cases with COVID-19 were selected. Combined data revealed that the overall proportion of hematological cancer patients with COVID-19 was 16.5% (95% CI 0.130 - 0.208, p ≤ 0.001). The stratified analysis by ethnicity showed that the proportion was 18.8% and 12.4% in Caucasian and Asian hematological cancer patients with COVID-19, respectively. Moreover, subgroup analysis by country of origin showed that its proportion was the highest in the United Kingdom (22.5%), followed by France (17.1%) and China (8.2%). Conclusion This meta-analysis result indicated that the proportion of hematological cancer patients with SARS-CoV-2 infection during the COVID-19 pandemic was 16.5%. Further larger sample sizes and multicenter studies among different ethnic groups are necessary to get a better assessment of the proportion.

Abstract Objective Previous studies investigating the association between angiotensin-converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism and recurrent pregnancy loss (RPL) risk has provided inconsistent results. The aim of our study was to assess the association between the ACE I/D polymorphism and risk of RPL. Methods All studies published up to January 30, 2018 on the association of ACE I/D polymorphism with RPL were identified by searching the PubMed, Web of Knowledge, and Google scholar databases. Results A total of 26 case-control studies with 3,140 RPL cases and 3,370 controls were included in themeta-analysis. Overall, there was a significant association between ACE I/D polymorphism and RPL risk under the allele model (I versus D: odds ratio [OR] = 0.538, 95% confidence interval [CI] = 0.451-0.643, p 0.001), the homozygote model (II versus DD: OR = 0.766, 95% CI = 0.598-0.981, p = 0.035) and the recessive model (II versus ID + DD: OR = 0.809, 95% CI = 0.658-0.994, p = 0.044). Subgroup analysis by ethnicity showed that there was a significant association between ACE I/D polymorphism and increased risk of RPL in Caucasian and West-Asian populations, but not in East-Asians. When stratified by number of recurrent miscarriages (RMs), a significant association between ACE I/D polymorphism and increased risk of RPL was detected in the group of studies with ≥ 2 RMs, but not in studies with ≥ 3 RMs. Conclusion Themeta-analysis suggests that ACE I/D polymorphism is associated with increased risk of RPL. The ACE I/D polymorphism may be a risk factor for RPL in Caucasian and West-Asian populations, but not in East-Asians.

RESUMO CONTEXTO: Vários estudos epidemiológicos têm investigado a associação de polimorfismo da região promotora do gene interleucina-10 (IL-10) com câncer colorretal (CRC), mas por enquanto a conclusão ainda é conflitante e inconclusiva. OBJETIVO: Foi realizada esta meta-análise para avaliar a associação de polimorfismo da região promotora do Il-10 com o câncer colorretal. MÉTODOS: Os artigos elegíveis foram identificados por uma pesquisa de várias bases de dados bibliográficas para o período até 15 de março de 2018. A força da associação foi medida por odds ratio (OR) com intervalos de 95% de confiança (IC). RESULTADOS: Um total de 28 estudos de casos-controles com 5.647 casos de câncer colorretal e 6.908 controles foram selecionados, incluindo 14 estudos para o polimorfismo de IL-10-1082A>G (rs1800896) (2.702 casos e 3.649 controles), 11 estudos para-592C>A (rs1800872) polimorfismo (3.259 casos e 4.992 controles), e três estudos para-819T>C (rs1800871) polimorfismo (477 casos e 544 controles). Ao reunir todos os estudos elegíveis, verificou-se que o Il-10-1082A>G e-592C>A polimorfismo não foram associados com o aumento do risco de câncer colorretal na população global. No entanto, houve associações significativas entre o polimorfismo IL-10-819T>C e a susceptibilidade de câncer colorretal o modelo alelo (A vs G: OR=1,278; 95% CI 1,043-1,566; P=0,018) e o modelo recessivo (AA vs AG + GG: ou =1,709; 95% CI 1,026-2,845; P=0,039). CONCLUSÃO: Nesta meta-análise revelou-se que o polimorfismo IL-10-819T>C foi associado a um risco significativamente maior de câncer colorretal; enquanto o Il-10-1082A>G e-592C>A polimorfismos não foram associados com o risco de câncer colorretal. O polimorfismo IL-10-819T>C pode ser importante como fator preditivo suspeito da ocorrência de câncer colorretal.

ABSTRACT BACKGROUND: Several epidemiological studies have investigated the association of promoter region polymorphisms of Interleukin-10 (IL-10) gene with colorectal cancer (CRC), while the conclusion is still conflicting and inconclusive. OBJECTIVE: We conducted this meta-analysis to evaluate the association of promoter region polymorphisms of IL-10 with CRC. METHODS: Eligible articles were identified by a search of several bibliographic databases for the period up to March 15, 2018. The strength of the association was measured by odd ratios with 95% confidence intervals. RESULTS: A total of 28 case-control studies with 5,647 CRC cases and 6,908 controls were selected, including 14 studies for IL-10 -1082A>G (rs1800896) polymorphism (2,702 cases and 3,649 controls), eleven studies for -592C>A (rs1800872) polymorphism (3,259 cases and 4,992 controls), and three studies for -819T>C (rs1800871) polymorphism (477 cases and 544 controls). By pooling all eligible studies, we found that the IL-10 -1082A>G and -592C>A polymorphisms were not associated with increased CRC risk in overall population. However, there was significant associations between the IL-10 -819T>C polymorphism and CRC susceptibility under the allele model (A vs G: OR=1.278, 95% CI 1.043-1.566, P=0.018) and the recessive model (AA vs AG+GG: OR=1.709, 95% CI 1.026-2.845, P=0.039). CONCLUSION: In this meta-analysis we found that IL-10 -819T>C polymorphism was associated with significantly increased risk of CRC; while the IL-10 -1082A>G and -592C>A polymorphisms were not associated with CRC risk. The IL-10 -819T>C polymorphism may be important as suspected predictive factor of CRC occurrence.